Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies | Aplastic Anemia and MDS International Foundation

Clinical Trial: NCT02556931

Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies
For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
Purpose: 

To see if it is possible to use short-duration tacrolimus after a peripheral blood stem cell transplant in certain malignancies that are considered difficult to engraft.

Status: 
Recruiting
Study Date: 
Sun, 11/01/2015 to Sun, 12/01/2019
Bone Marrow Disease(s): 
myelodysplastic syndromes (MDS)
Associated Drug(s): 
Intervention: 
Drug: Fludarabine Days -6 through -2: 30 mg/m^2 IV daily Other Name: Fludara Drug: Cyclophosphamide Days -6 through -5: 14.5 mg/kg IV daily Other Names: Cytoxan Cy Radiation: Total body irradiation Day -1: 200 cGy in a single fraction Other Name: TBI Drug: Tacrolimus Start on Day 5 through either Day 90 or Day 180 depending on GVHD status Other Names: Prograf FK506 FK-506 Drug: Mycophenolate mofetil Days 5 through 35: 15 mg/kg PO three times daily (max 3 g/day) Other Names: MMF CellCept